

1 **Global emergence of resistance to fluconazole and**  
2 **voriconazole in *Candida parapsilosis* in tertiary hospitals in**  
3 **Spain during the COVID-19 pandemic**

4 Oscar Zaragoza<sup>1,2\*</sup>, Laura Alcázar-Fuoli<sup>1,2</sup>, Nuria Trevijano-Contador<sup>1</sup>, Alba Torres-  
5 Cano<sup>1</sup>, Cristina Carballo-González<sup>1</sup>, Mireia Puig-Asensio<sup>3,4</sup>, María Teresa Martín-  
6 Gómez<sup>5</sup>, Emilio Jiménez-Martínez<sup>3</sup>, Daniel Romero<sup>5</sup>, Francesc Xavier Nuvials<sup>6</sup>,  
7 Roberto Olmos-Arenas<sup>7</sup>, María Clara Moretó-Castellsagué<sup>7</sup>, Lucía Fernández-  
8 Delgado<sup>7</sup>, Graciela Rodríguez-Sevilla<sup>7</sup>, María-Mercedes Aguilar-Sánchez<sup>7</sup>, Josefina  
9 Ayats-Ardite<sup>7</sup>, Carmen Ardanuy-Tisaire<sup>7</sup>, Isabel Sanchez-Romero<sup>8</sup>, María Muñoz-  
10 Algarra<sup>8</sup>, Paloma Merino-Amador<sup>9</sup>, Fernando González-Romo<sup>9</sup>, Gregoria Megías-  
11 Lobón<sup>10</sup>, Jose Angel García-Campos<sup>10</sup>, María Ángeles Mantecón-Vallejo<sup>10</sup>, María  
12 Teresa Durán-Valle<sup>11</sup>, Arturo Manuel Fraile-Torres<sup>11</sup>, María Pía Roiz-Mesones<sup>12</sup>, Isabel  
13 Lara-Plaza<sup>12</sup>, Ana Perez de Ayala<sup>13</sup>, María Simón-Sacristán<sup>14</sup>, Ana Collazos-Blanco<sup>14</sup>,  
14 Teresa Nebreda-Mayoral<sup>15</sup>, Gabriel March-Roselló<sup>15</sup>.

- 15
- 16 1) Mycology Reference Laboratory. National Centre for Microbiology. Instituto de Salud
  - 17 Carlos III. Carretera Majadahonda-Pozuelo, Km2. Majadahonda 28220. Madrid. Spain.
  - 18 2) Center for Biomedical Research in Network in Infectious Diseases
  - 19 (CIBERINFEC-CB21/13/00105), Instituto de Salud Carlos III, Madrid, Spain.
  - 20 3) Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut
  - 21 d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  - 22 4) Center for Biomedical Research Network in Infectious Diseases (CIBERINFEC;
  - 23 CB21/13/00009), Instituto de Salud Carlos III, Madrid, Spain
  - 24 5) Department of Microbiology, Vall D'Hebron University Hospital, Universitat Autònoma
  - 25 de Barcelona, Barcelona, Spain.
  - 26 6) Intensive Care Unit, Vall D'Hebron University Hospital, Universitat Autònoma de
  - 27 Barcelona, Spain.
  - 28 7) Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
  - 29 8) Microbiology Department, Hospital Universitario Puerta de Hierro, Majadahonda,
  - 30 Madrid, Spain;
  - 31 9) Microbiology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain;
  - 32 Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain;
  - 33 Department of Medicine, Universidad Complutense School of Medicine, Madrid, Spain.
  - 34 10) Department of Clinical Microbiology. Hospital Universitario de Burgos
  - 35 11) Microbiology and Parasitology Department. Hospital Universitario de Móstoles
  - 36 12) Microbiology Department, Marqués de Valdecilla University Hospital, Santander.
  - 37 Cantabria. España. Instituto de Investigación Valdecilla (IDIVAL).
  - 38 13) Microbiology Unit. University Hospital 12 de Octubre. Madrid, Spain
  - 39 14) Microbiology and Parasitology Department. Hospital Central de la Defensa Gómez Ulla.
  - 40 Madrid, Spain.
  - 41 15) Microbiology and Immunology Unit. University Clinic Hospital of Valladolid
  - 42

43

44 **\*Corresponding author: Oscar Zaragoza**

45 Email for correspondence: [ozaragoza@isciii.es](mailto:ozaragoza@isciii.es)

46

47 **Running title:** FLZ resistance in *C. parapsilosis*

48 **ABSTRACT**

49

50 **Background:** *Candida parapsilosis* is a frequent cause of candidemia  
51 worldwide. Its incidence is associated with the use of medical implants, such as  
52 central venous catheters or parenteral nutrition. This species has reduced  
53 susceptibility to echinocandins and is susceptible to polyenes and azoles.  
54 Multiple outbreaks caused by fluconazole non-susceptible strains have been  
55 reported recently. A similar trend has been observed among the *C. parapsilosis*  
56 isolates received in the last two years at the Spanish Mycology Reference  
57 Laboratory.

58

59 **Methods:** Yeast were identified by molecular biology and antifungal  
60 susceptibility testing was performed using EUCAST protocol. *ERG11* gene was  
61 sequenced to identify resistance mechanisms, and typification was carried out  
62 by microsatellite analysis.

63

64 **Results:** We examined the susceptibility profile of the *C. parapsilosis* isolates  
65 available at our Reference Laboratory since 2000 (around 1,300 strains).  
66 During the last two years, the number of isolates with acquired resistance to  
67 fluconazole and voriconazole has increased in at least eight different Spanish  
68 hospitals. Typification of the isolates revealed that some prevalent clones had  
69 spread through several hospitals of the same geographical region. One of these  
70 clones was found in hospitals from the region of Catalonia, another in hospitals  
71 from Madrid and Burgos, and two other different genotypes from Santander.

72

73 **Conclusions:** Our data suggests that the epidemiological situation caused by  
74 the COVID-19 pandemic might have induced a selection of fluconazole-  
75 resistant *C. parapsilosis* isolates that were already present at the hospitals.  
76 Further measures must be taken to avoid the establishment of clinical outbreaks  
77 that could threaten the life of infected patients.

78

79 **Keywords:** *Candida parapsilosis*; fluconazole; voriconazole; antifungal  
80 resistance, outbreaks.

81

82

## 83 INTRODUCTION

84

85 *Candida parapsilosis* is an opportunistic pathogenic yeast able to cause  
86 invasive diseases such as candidemia. Worldwide, it is the third cause of  
87 bloodborne yeast infection after *C. albicans* and *C. glabrata*, although in some  
88 countries, its incidence is higher and above *C. glabrata* [1-4]. Neonates, as well  
89 as indwelling parenteral nutrition and central nervous catheters have been  
90 associated to a higher risk of infection [5, 6]. Besides sporadic infections, *C.*  
91 *parapsilosis* is well known to cause nosocomial outbreaks through direct and  
92 indirect contact via the hands of health care workers and through contaminated  
93 patient care equipment.

94 *Candida parapsilosis* exhibits a reduced natural in vitro susceptibility to  
95 echinocandins [7], so the main therapeutic options for invasive infections due to  
96 this species are the triazoles, mainly fluconazole or, alternatively, polyenes.  
97 Acquired resistance to fluconazole in *C. parapsilosis* is a rare phenomenon,  
98 being less than 5% of isolates in different epidemiological studies [2, 7-10]. In  
99 recent years, however, a steady increase of resistance has been observed  
100 worldwide, mostly in the context of nosocomial outbreaks [11-20]. In many  
101 cases, these outbreaks are monoclonal, and are associated to mutations in  
102 *ERG11* (mainly with the Y132F mutation), overexpression of efflux pumps (as  
103 Mdr1 and Cdr1) and mutations in *MRR1*, which encodes a transcription factor  
104 that regulates the expression of some efflux pumps [11-13, 16, 18, 21, 22].

105

106 The National Centre for Microbiology from Instituto de Salud Carlos III (CNM-  
107 ISCIII, Madrid, Spain) acts as a national reference center for clinically isolated  
108 fungi, providing services such as genotyping and confirmation of antifungal  
109 susceptibility profiles by the EUCAST standardized methodology. Since 2020 a  
110 significant increase in the number of fluconazole non-susceptible (FNS) *C.*  
111 *parapsilosis* isolates received was noted, most of them coming from tertiary  
112 hospitals across the country reporting to have a strong epidemiological  
113 suspicion of ongoing outbreaks.

114

115 The aim of this work was to describe the antifungal susceptibility profile of all  
116 the *C. parapsilosis* isolates received in the Spanish Mycology Reference  
117 Laboratory (SMRL) since 2000 to get insights about susceptibility profile and  
118 appearance of resistance in this species. Typing analysis confirmed genetic  
119 relatedness between isolates and suggested that in Spain there could be an  
120 expansion of *C. parapsilosis* resistant isolates among tertiary care hospitals.  
121 The fact that this expansion overlaps with the impact of the COVID-19  
122 pandemic, highlights a worrisome situation in which resistance to azoles in *C.*  
123 *parapsilosis* could be emerging worldwide.

124

125

## 126 **MATERIAL AND METHODS**

127

### 128 **Media and strains identification**

129 The isolates were primarily isolated, identified and screened for fluconazole  
130 non-susceptibility at the local laboratories following the routine methodologies of  
131 each center. Isolates sent to the CNM-ISCIII since 2000 and identified as  
132 *C. parapsilosis* were subcultivated onto Sabouraud solid or liquid medium.  
133 Identification was confirmed by sequencing the internal transcribed spacer 1  
134 (ITS1) and ITS2 regions from the ribosomal DNA as previously in [23].

135

### 136 **Antifungal susceptibility**

137 Antifungal susceptibility testing was performed following EUCAST protocol  
138 (RPMI 1640 medium (Merck, Sigma-Aldrich) buffered with MOPS (Merck,  
139 Sigma-Aldrich) at pH 7 and supplemented with 2% glucose (Merck, Sigma-  
140 Aldrich), [24]).The following antifungals were tested in the concentration range  
141 indicated in brackets: Amphotericin B (AmB, Merck, Sigma-Aldrich, 16-0.03  
142 mg/L), flucytosine (64-0.125 mg/L), fluconazole (FLC, Merck, Sigma-Aldrich, 64-  
143 0.125 mg/L), itraconazole (ITZ, Janssen Pharmaceutical Research and  
144 Development, 8-0.016 mg/L), voriconazole (VOR, Pfizer Pharmaceutical Group,  
145 8-0.016 mg/L), posaconazole (POS, Merck, Sigma-Aldrich, 8-0.016 mg/L),  
146 isavuconazole (ISV, Pfizer Pharmaceutical Group, 8-0.016 mg/L), caspofungin  
147 (CSP, Merck, Sigma-Aldrich, 16-0.016 mg/L), micafungin (MICA, Astellas  
148 Pharma Inc, 2-0.004 mg/L) and anidulafungin (ANID, Pfizer Pharmaceutical

149 Group, 4-0.008 mg/L). The Minimal inhibitory concentration (MIC) was defined  
150 as the concentration that caused 50% of growth inhibition compared to the  
151 control well without antifungal, except for amphotericin B (90%). Strains were  
152 categorized as susceptible (S), resistant (R) or intermediate (I, susceptible,  
153 increased exposure) following the breakpoints established by EUCAST (see  
154 <https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals>, document from February 4<sup>th</sup>,  
155 2020). Control strains *C. parapsilosis* ATCC 22019 and *C. krusei* ATCC 6258  
156 were included in all the assays.

157

### 158 **Sequencing of the *ERG11* gene.**

159 To identify mutations at the *ERG11* gene, different primers were designed (see  
160 table 1). The whole gene was amplified using oligonucleotides 01\_F and 02\_R  
161 using the following PCR conditions: 94°C for 2 min and 35 cycles of  
162 amplification (94°C for 30 s, 56°C for 45 s and 72°C for 2 min) followed by a 1  
163 final cycle of 5 min of 72°C.

164 The PCR products were purified with ExoStart kit. Sanger sequencing was  
165 performed using all the oligonucleotides described in table 1, and analyzed with  
166 Seqman software (DNA Lasergene 12 package).

167

### 168 **Microsatellite typing**

169 A panel of four short tandem repeat (STR) markers was used for genotyping the  
170 *C. parapsilosis* isolates. Three trinucleotide repeat and one hexanucleotide  
171 repeat markers described by Diab-Elschahawi [25] were independently  
172 amplified by PCR. Amplifications reactions were performed in a final volume of  
173 20 µl for markers 3A, 3B and 6A, containing 1 ng of genomic DNA, 0.5 µM  
174 amplification primers, 120 µM of dNTPS, 1.25 mM MgCl<sub>2</sub> and 1 U of Amplitaq™  
175 DNA (Applied Biosystems). The PCR conditions used were: initial  
176 denaturalization for 5 min at 95 °C, followed by 30 cycles of 15 s of  
177 denaturalization at 95 °C, 1 min of annealing at 62 °C, and 1 min of extension at  
178 72 °C. A final incubation of 7 min at 72 °C was included in the protocol. The  
179 PCR conditions were optimized for the “3C” marker. In this case, amplifications  
180 reactions were performed in a final volume of 50 µl, containing a 1 ng of DNA,  
181 0.2 µM amplification primers, 0.05 mM of dNTPS, 0.3 mM MgCl<sub>2</sub> and 1 U of  
182 Amplitaq™ DNA (Applied Biosystems). PCR conditions for 3C marker were as

183 follows: initial denaturalization for 5 min at 94 °C, followed by 35 cycles of 30 s  
184 of denaturalization at 94 °C, 45 s of annealing at 60 °C, and 1 min of extension  
185 at 72 °C followed of 5 min at 72 °C. Then, 10 µl of the amplification products  
186 were put on PCR Plate 96 semi-skirted (Eppendorf) and purified with AMPure  
187 XP (Beckman Coulter) using SPRI beads technology in an Eppendorf ep Motion  
188 5075 (Eppendorf). Finally, a 1 µl aliquot of PCR product was added to a 9 µl of  
189 Formamide and to a 1 µl of internal size marker GeneScan™ 500 ROX™  
190 (Applied Biosystems). After denaturalization of the samples at 95 °C for 3 min  
191 and rapid cooling to 4 °C, they were run onto a AB3730XL DNA analyzer  
192 (Applied Biosystems). Allele sizes analysis was performed with the Peak  
193 scanner software (Applied Biosystems) and according the internal lane size  
194 standard GeneScan™ 500 ROX™.

195

196 Similarities between genotypes were visualized by constructing a minimum  
197 spanning tree using InfoQuest FP, version 4.5 (Applied Maths, St.-Martens-  
198 Latem, Belgium), treating the data as categorical information.

199

## 200 **Data analysis and Statistics**

201 MIC analysis was performed with SPSS software. For each year, the  
202 distribution of MICs was reported. We also calculated the geometric mean of  
203 the MICs values, the median, and the minimal and maximal values of the  
204 distributions.

205

206

## 207 **RESULTS AND DISCUSSION**

208

209 We collected all the isolates available at our laboratory (SMRL), and analysed  
210 the evolution of the antifungal susceptibility pattern from 2000 to 2021. A total of  
211 1,301 isolates were studied. As shown in table 1, resistance to fluconazole  
212 remained low (3-7%) among the isolates from our collection until 2016.  
213 However, a dramatic change in this resistance rate among the isolates received  
214 at the Reference Laboratory was noted thereafter, being particularly notable  
215 from 2019 onwards. Throughout the latter period, the percentage of fluconazole  
216 resistance significantly increased (27% in 2019, around 60% in 2020 and 2021,

217 see table 2) as compared to previous years. This trend was also observed for  
218 voriconazole (Table 3). Before 2019, the voriconazole resistance rate was  
219 below 2%, but since 2020, the percentage of susceptible increased exposure (I,  
220 MIC = 0.25 mg/L) and resistant strains (MIC>0.25 mg/L) increased up to around  
221 60% among the strains received at the laboratory.

222

223 Regarding itraconazole and posaconazole, there was a slight trend to higher  
224 MICs, but they were still categorized as susceptible (Table 4 and 5). Only three  
225 isolates were fully resistant to fluconazole, voriconazole, itraconazole and  
226 posaconazole. For isavuconazole, although there are not breakpoints to define  
227 resistant strains, an increase in the MICs among the isolates received since  
228 2020 was found. The isavuconazole modal MIC rose from 0.016 mg/L before  
229 2020 to 0.06 mg/L later on (table 6), similarly to what was observed for  
230 itraconazole and posaconazole.

231

232 The presence of *ERG11* mutations in fluconazole non-susceptible isolates was  
233 investigated. The *ERG11* gene of 230 strains from 2020 and 2021, including S  
234 (n=34), I (susceptible, increased exposure, n=7) and R (n=189) strains to FLC  
235 was sequenced. The *ERG11* gene was found to be wild-type in all the  
236 susceptible strains, and in 4.8% of the FNS isolates. Among the latter (n=11),  
237 one strain was also susceptible increased exposure (I) and six resistant to  
238 voriconazole. The remaining fluconazole-resistant isolates (n=178, 95.2%)  
239 harbored the Y132F mutation, which has already been associated to FLC  
240 resistance in *C. parapsilosis* (Table 7). In addition, we found that one of the  
241 resistant isolates harbored the K143R mutation in *ERG11* gene, which has  
242 been detected in azole non-susceptible strains causing monoclonal outbreaks  
243 in India [26] and also in combination with the Y132F mutation [11]. This  
244 mutation has also been associated with pan-azole resistance in *C. tropicalis*  
245 [27]. Another strain harbored the G458S mutation, which has also been related  
246 to azole resistance in *Candida parapsilosis* [4, 28]. Finally, many isolates  
247 harbored the R398I (data not shown), but this mutation was also found in  
248 several susceptible isolates, which suggest that it is not related to FLZ  
249 resistance.

250

251 Interestingly, in up to 35% of the FNS strains, the Y132F substitution was found  
252 in heterozygosis. Thus, we analysed if the triazole MIC distribution differed  
253 among homozygous or heterozygous strains. We observed that strains that  
254 harbored the Y132F mutation in homozygosis had higher MICs to fluconazole  
255 (Geometric Mean = 26.1 mg/L) compared to those strains carrying the mutation  
256 in heterozygosis (Geometric Mean = 12.5). A similar situation was found for  
257 voriconazole (GM of heterozygous strains = 0.39 mg/L vs GM for homozygous  
258 strains = 0.5 mg/L). The Y132F substitution did not have a significant influence  
259 on the susceptibility to isavuconazole, posaconazole and itraconazole.  
260 Moreover, for these three antifungals, the Y132F mutation in homozygosis  
261 tended to result in lower GM than in heterozygous strains (table 8).

262

263 To investigate if there was any genetic correlation between the FNS strains, we  
264 performed a microsatellite-based genotyping of 256 *C. parapsilosis* (from 2019,  
265 2020 and 2021) isolates from 220 different patients and 8 environmental  
266 strains, including 81 susceptible, 6 susceptible increased exposure and 168  
267 resistant isolates. Among the susceptible isolates, we included strains from the  
268 same hospitals that had resistant strains, but also others not related to these  
269 outbreaks. Microsatellite genotyping identified 118 different genotypes. The  
270 relationship between the obtained genotypes is illustrated in Fig. 1 and  
271 supplemental table 1.

272

273 As compared to the FNS isolates, the genotypic variability was greater among  
274 fluconazole-susceptible strains, what could be attributed, in part to the fact that  
275 most of the susceptible strains were recovered from unrelated cases.

276

277 Remarkably, in the case of contemporary resistant isolates there was a  
278 markedly well-defined geographical distribution of genotypes. Genotype 10 was  
279 found among strains of two hospitals from the area of Barcelona (Bellvitge and  
280 Vall d'Hebron Hospitals), and in an isolate from 2019 stored in the collection  
281 and recovered in another center located in the metropolitan area of Barcelona.  
282 These two hospitals also shared the closely related genotype 12. Neither  
283 genotype 10, nor genotype 12 were found in centers from other regions in  
284 Spain. Genotype 96 was found to be highly prevalent among isolates obtained



285 from centers located in Madrid and in Burgos. Genotype 95, despite being  
286 much less prevalent, was identified in two centers of the Madrid metropolitan  
287 area. Genotypes 67 and 75 were found exclusively in a hospital at the north of  
288 Spain (Santander), geographically distant from Madrid and Barcelona.  
289 Additionally, fluconazole susceptible strains isolated in the context of another  
290 nosocomial outbreak (Universitary Clinic Hospital from Valladolid) were  
291 received, displaying genotypes clearly different from the abovementioned and  
292 closely related to each other (genotypes 45 to 50). A geographical distribution  
293 of the genotypes of the resistant strains is shown in figure 1.

294

295 A minimum spanning tree was built, showing that some genotypes have  
296 evolved by spontaneous changes in one of the microsatellite markers. The  
297 microsatellite analysis showed a distribution of clades that grouped by  
298 geographic origin, with resistant strains clustering together (Figure 2).

299

300 Our work shows a significant increase in the number of *C. parapsilosis* resistant  
301 to fluconazole and voriconazole received at the SMRL from several Spanish  
302 hospitals and arising in a relatively short period. This isolates seem to be part of  
303 outbreaks that have emerged almost simultaneously in distant cities, and that  
304 can be attributed to clones that are shared almost exclusively among  
305 geographically close related centers. From these data it cannot be inferred a  
306 generalized increment in the fluconazole resistance among Spanish isolates of  
307 *C. parapsilosis* since it is not mandatory to inform about all the infections  
308 caused by these species. It should be noted that another outbreak of FNS *C.*  
309 *parapsilosis* has been recently described in the Balearic Islands (Son Espases  
310 Hospital) [29], which supports the hypothesis that fluconazole resistant strains  
311 from *C. parapsilosis* may have emerged and spread in Spain in the last two  
312 years. All together, our data is in sharp contrast to what have being described in  
313 the several former epidemiological studies that have been carried out in Spain  
314 [6, 7, 30, 31], suggesting a new and worrisome change in the epidemiological  
315 incidence of FNS *C. parapsilosis* strains.

316

317 Recent emergence of FNS isolates in *C. parapsilosis* has been described in  
318 other countries in the literature [11-20], so our data supports that the increase of

319 azole resistance in *C. parapsilosis* might be a global problem. In this study, the  
320 majority of resistant isolates harbored the Y132F mutation, which has been  
321 largely associated in the literature with the appearance of clonal outbreaks.  
322 However, we also detected a few isolates that did not have this mutation. For  
323 this reason, further studies should be performed to describe all the resistance  
324 mechanisms circulating among Spanish hospitals.

325

326 At the moment, the reasons for the increase in the incidence of azole-resistant  
327 *C. parapsilosis* strains in Spain are unknown, but we hypothesized that this  
328 phenomenon may be related to the negative impact that the COVID-19  
329 pandemic has had in Spanish hospitals for several reasons. First, there is a  
330 clear temporal correlation between the increase in the number of resistant  
331 isolates received at the reference laboratory and clinical impact of the  
332 pandemic. Second, the COVID-19 pandemic has resulted in a severe  
333 overcrowding of hospitals, and in particular, of Intensive Care Units, along with  
334 the necessity of recruiting large numbers of healthcare professionals that were  
335 not properly trained in infection control measures. Third, during the pandemic  
336 there were changes in personal protective equipment use and the same gloves  
337 could have been used between patients [32, 33]. This might have increased the  
338 risk of cross-transmission between patients and caused hospital outbreaks.  
339 Furthermore, during the pandemic, there has been a significant transfer of  
340 patients between different hospitals, which might have contributed to the  
341 dispersion of resistant clones between clinical tertiary centres. A similar  
342 situation has been described in multicenter studies in India [26], which  
343 highlights the ability of FNS isolates to spread and colonize hospital  
344 environments. Interestingly, some of the analyzed samples in our work were  
345 isolated from environmental origin in the hospital and were also found in clinical  
346 samples from the same center. This correlation suggests that *C. parapsilosis*  
347 clones might have colonized the hospital surfaces, which increases the risk of  
348 recirculating among patients along the time and, in parallel, increases the risk of  
349 invasive infections among the most fragile ones. Previous studies, in fact, have  
350 shown, not only an increase incidence of *C. parapsilosis* infections in COVID-19  
351 patients [34], but also other fungal diseases, such as Covid Associated

352 Pulmonary Aspergillosis (CAPA) [35-37], mucormycosis [38-40] and *Candida*  
353 infections [41, 42] (see reviews in [43, 44]).

354

355 The impact of the COVID-19 pandemic and clinical management of the patients  
356 does not fully explain why there has been a selection of azole-resistant strains,  
357 and why these genetically different resistant strains have emerged almost  
358 simultaneously in distant places across Spain. An increase in the use of  
359 antimicrobials has been reported since the appearance of the COVID-19  
360 pandemic in some geographical regions [45]. Among azoles, an increase in the  
361 use of echinocandins and voriconazole has been reported [45], which might  
362 have favoured the selection of fluconazole and voriconazole-resistant *C.*  
363 *parapsilosis*. Another possibility is that resistance to azoles affects virulence  
364 traits. In this sense, it has been described that *C. parapsilosis* strains harboring  
365 the Y132F mutation in *ERG11* have reduced ability to form biofilms [11], which  
366 rises the hypothesis that these strains have a higher ability to spread and  
367 disseminate. Furthermore, several studies have associated the incidence of  
368 resistant strains with higher mortality of the patients [11, 28], which warrants  
369 further studies on the virulence of FLZ non-susceptible *C. parapsilosis* strains.  
370 In our case, the clinical management of the patients might have contributed to  
371 the selection of pre-existing resistant clones circulating in the hospitals previous  
372 to the COVID-19 pandemic [46]. In our case, this idea is supported by the fact  
373 that we identified that some of the resistant clones were already present in our  
374 collection in samples from 2019. For these reason, it is required to develop  
375 future research lines to investigate the genetic proximity of the resistant  
376 isolates, and compare them not only between different hospitals, but also to  
377 those described in different countries.

378

379 Despite the epidemiological limitations and interpretations of our work, we  
380 believe that the data herein presented is an indicator of an emerging clinical  
381 problem, that is, the selection of azole-resistance in *C. parapsilosis* during the  
382 COVID-19 pandemic. We also would like to highlight that the increase in FLZ-  
383 resistant isolates in tertiary hospitals in Spain is agreement with the worldwide  
384 context, where an increasing number of outbreaks is being reported. We  
385 encourage the clinical community to investigate the presence of these clones in

386 the hospital environment, as well as to make an effort to perform susceptibility  
387 testing in strains from non-invasive origin (colonization, isolated from hospital  
388 surfaces, etc) and to design specific measures to prevent the expansion of the  
389 associated resistance mechanisms.

390

### 391 **Acknowledgements and Funding**

392

393 O.Z. was funded by grants SAF2017-86912-R and PID2020-114546RB-I00  
394 from the Spanish Ministry for Science and Innovation. This work was also  
395 funded by the National Centre for Microbiology (Instituto de Salud Carlos III)  
396 through the Surveillance program of Antifungal Resistance and the Center for  
397 Biomedical Research in Network in Infectious Diseases (CIBERINFECT  
398 CB21/13/00105 (OZ and LAF) and CB21/13/00009 (M.P-A). L.A-F. was  
399 supported by Fondo de Investigación Sanitaria (MPY 117/18 and MPY 305/20).

400

### 401 **Conflict of interest**

402 The authors have no conflict of interest to declare

403

404

405

### 406 **REFERENCES**

407

- 408 1. Toth R, Nosek J, Mora-Montes HM, et al. *Candida parapsilosis*: from  
409 Genes to the Bedside. Clin Microbiol Rev 2019; 32(2).
- 410 2. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty  
411 Years of the SENTRY Antifungal Surveillance Program: Results for  
412 *Candida* Species From 1997-2016. Open Forum Infect Dis 2019; 6(Suppl  
413 1): S79-S94.
- 414 3. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the  
415 epidemiological landscape of invasive candidiasis. J Antimicrob  
416 Chemother 2018; 73(suppl\_1): i4-i13.
- 417 4. Arastehfar A, Lass-Flörl C, Garcia-Rubio R, et al. The Quiet and  
418 Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. J  
419 Fungi (Basel) 2020; 6(3).

- 420 5. Yamin DH, Husin A, Harun A. Risk Factors of *Candida parapsilosis*  
421 Catheter-Related Bloodstream Infection. *Front Public Health* 2021; 9:  
422 631865.
- 423 6. Puig-Asensio M, Padilla B, Garnacho-Montero J, et al. Epidemiology and  
424 predictive factors for early and late mortality in *Candida* bloodstream  
425 infections: a population-based surveillance in Spain. *Clin Microbiol Infect*  
426 2014; 20(4): O245-54.
- 427 7. Guinea J, Zaragoza O, Escribano P, et al. Molecular identification and  
428 antifungal susceptibility of yeast isolates causing fungemia collected in a  
429 population-based study in Spain in 2010 and 2011. *Antimicrob Agents*  
430 *Chemother* 2014; 58(3): 1529-37.
- 431 8. Iatta R, Caggiano G, Cuna T, Montagna MT. Antifungal susceptibility  
432 testing of a 10-year collection of *Candida* spp. isolated from patients with  
433 candidemia. *J Chemother* 2011; 23(2): 92-6.
- 434 9. Ziccardi M, Souza LO, Gandra RM, et al. *Candida parapsilosis* (sensu  
435 lato) isolated from hospitals located in the Southeast of Brazil: Species  
436 distribution, antifungal susceptibility and virulence attributes. *Int J Med*  
437 *Microbiol* 2015; 305(8): 848-59.
- 438 10. Battistolo J, Glampedakis E, Damonti L, et al. Increasing Morbidity and  
439 Mortality of Candidemia over One Decade in a Swiss University Hospital.  
440 *Mycoses* 2021.
- 441 11. Arastehfar A, Daneshnia F, Hilmioglu-Polat S, et al. First Report of  
442 Candidemia Clonal Outbreak Caused by Emerging Fluconazole-  
443 Resistant *Candida parapsilosis* Isolates Harboring Y132F and/or  
444 Y132F+K143R in Turkey. *Antimicrob Agents Chemother* 2020; 64(10).
- 445 12. Choi YJ, Kim YJ, Yong D, et al. Fluconazole-Resistant *Candida*  
446 *parapsilosis* Bloodstream Isolates with Y132F Mutation in ERG11 Gene,  
447 South Korea. *Emerg Infect Dis* 2018; 24(9): 1768-70.
- 448 13. Corzo-Leon DE, Peacock M, Rodriguez-Zulueta P, Salazar-Tamayo GJ,  
449 MacCallum DM. General hospital outbreak of invasive candidiasis due to  
450 azole-resistant *Candida parapsilosis* associated with an Erg11 Y132F  
451 mutation. *Med Mycol* 2021; 59(7): 664-71.

- 452 14. Fekkar A, Blaize M, Bougle A, et al. Hospital outbreak of fluconazole-  
453 resistant *Candida parapsilosis*: arguments for clonal transmission and  
454 long-term persistence. *Antimicrob Agents Chemother* 2021.
- 455 15. Govender NP, Patel J, Magobo RE, et al. Emergence of azole-resistant  
456 *Candida parapsilosis* causing bloodstream infection: results from  
457 laboratory-based sentinel surveillance in South Africa. *J Antimicrob*  
458 *Chemother* 2016; 71(7): 1994-2004.
- 459 16. Martini C, Torelli R, de Groot T, et al. Prevalence and Clonal Distribution  
460 of Azole-Resistant *Candida parapsilosis* Isolates Causing Bloodstream  
461 Infections in a Large Italian Hospital. *Front Cell Infect Microbiol* 2020; 10:  
462 232.
- 463 17. Mesini A, Mikulska M, Giacobbe DR, et al. Changing epidemiology of  
464 candidaemia: Increase in fluconazole-resistant *Candida parapsilosis*.  
465 *Mycoses* 2020; 63(4): 361-8.
- 466 18. Demirci-Duarte S, Arikan-Akdagli S, Gulmez D. Species distribution,  
467 azole resistance and related molecular mechanisms in invasive *Candida*  
468 *parapsilosis* complex isolates: Increase in fluconazole resistance in 21  
469 years. *Mycoses* 2021; 64(8): 823-30.
- 470 19. Thomaz DY, de Almeida JN, Jr., Lima GME, et al. An Azole-Resistant  
471 *Candida parapsilosis* Outbreak: Clonal Persistence in the Intensive Care  
472 Unit of a Brazilian Teaching Hospital. *Front Microbiol* 2018; 9: 2997.
- 473 20. Thomaz DY, Del Negro GMB, Ribeiro LB, et al. A Brazilian Inter-Hospital  
474 Candidemia Outbreak Caused by Fluconazole-Resistant *Candida*  
475 *parapsilosis* in the COVID-19 Era. *J Fungi (Basel)* 2022; 8(2).
- 476 21. Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular  
477 mechanisms of fluconazole resistance in *Candida parapsilosis* isolates  
478 from a U.S. surveillance system. *Antimicrob Agents Chemother* 2015;  
479 59(2): 1030-7.
- 480 22. Thomaz DY, de Almeida JN, Jr., Sejas ONE, et al. Environmental Clonal  
481 Spread of Azole-Resistant *Candida parapsilosis* with Erg11-Y132F  
482 Mutation Causing a Large Candidemia Outbreak in a Brazilian Cancer  
483 Referral Center. *J Fungi (Basel)* 2021; 7(4).
- 484 23. White T, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of  
485 fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand

- 486 DH, Sninsky JJ, White TJ. PCR protocols: a guide to methods and  
487 applications. San Diego, CA: Academic Press, 1990.
- 488 24. Arendrup MC, Meletiadis J, Mouton JW, et al. EUCAST technical note on  
489 isavuconazole breakpoints for *Aspergillus*, itraconazole breakpoints for  
490 *Candida* and updates for the antifungal susceptibility testing method  
491 documents. Clin Microbiol Infect 2016; 22(6): 571 e1-4.
- 492 25. Diab-Elschahawi M, Forstner C, Hagen F, et al. Microsatellite genotyping  
493 clarified conspicuous accumulation of *Candida parapsilosis* at a  
494 cardiothoracic surgery intensive care unit. J Clin Microbiol 2012; 50(11):  
495 3422-6.
- 496 26. Singh A, Singh PK, de Groot T, et al. Emergence of clonal fluconazole-  
497 resistant *Candida parapsilosis* clinical isolates in a multicentre laboratory-  
498 based surveillance study in India. J Antimicrob Chemother 2019; 74(5):  
499 1260-8.
- 500 27. Xisto MI, Caramalho RD, Rocha DA, et al. Pan-azole-resistant *Candida*  
501 *tropicalis* carrying homozygous erg11 mutations at position K143R: a  
502 new emerging superbug? J Antimicrob Chemother 2017; 72(4): 988-92.
- 503 28. Arastehfar A, Hilmioglu-Polat S, Daneshnia F, et al. Clonal Candidemia  
504 Outbreak by *Candida parapsilosis* Carrying Y132F in Turkey: Evolution  
505 of a Persisting Challenge. Front Cell Infect Microbiol 2021; 11: 676177.
- 506 29. Alcoceba E, Gomez A, Lara-Esbri P, et al. Fluconazole-resistant *Candida*  
507 *parapsilosis* clonally related genotypes: first report proving the presence  
508 of endemic isolates harbouring the Y132F ERG11 gene substitution in  
509 Spain. Clin Microbiol Infect 2022.
- 510 30. Peman J, Canton E, Quindos G, et al. Epidemiology, species distribution  
511 and in vitro antifungal susceptibility of fungaemia in a Spanish  
512 multicentre prospective survey. J Antimicrob Chemother 2012; 67(5):  
513 1181-7.
- 514 31. Canton E, Peman J, Quindos G, et al. Prospective multicenter study of  
515 the epidemiology, molecular identification, and antifungal susceptibility of  
516 *Candida parapsilosis*, *Candida orthopsilosis*, and *Candida metapsilosis*  
517 isolated from patients with candidemia. Antimicrob Agents Chemother  
518 2011; 55(12): 5590-6.

- 519 32. Sturdy A, Basarab M, Cotter M, et al. Severe COVID-19 and healthcare-  
520 associated infections on the ICU: time to remember the basics? *J Hosp*  
521 *Infect* 2020; 105(4): 593-5.
- 522 33. Abelenda-Alonso G, Puig-Asensio M, Jimenez-Martinez E, et al. Impact  
523 of the COVID-19 pandemic on infection control practices in a university  
524 hospital. *Infect Control Hosp Epidemiol* 2022: 1-8.
- 525 34. Cultrera R, Barozzi A, Libanore M, et al. Co-Infections in Critically Ill  
526 Patients with or without COVID-19: A Comparison of Clinical Microbial  
527 Culture Findings. *Int J Environ Res Public Health* 2021; 18(8).
- 528 35. Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-  
529 associated pulmonary aspergillosis (CAPA): a systematic review. *J Hosp*  
530 *Infect* 2021; 113: 115-29.
- 531 36. Thompson Iii GR, Cornely OA, Pappas PG, et al. Invasive Aspergillosis  
532 as an Under-recognized Superinfection in COVID-19. *Open Forum Infect*  
533 *Dis* 2020; 7(7): ofaa242.
- 534 37. Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive  
535 pulmonary aspergillosis among COVID-19 intubated patients: a  
536 prospective study. *Clin Infect Dis* 2020.
- 537 38. Singh K, Kumar S, Shastri S, Sudershan A, Mansotra V. Black fungus  
538 immunosuppressive epidemic with Covid-19 associated mucormycosis  
539 (zygomycosis): a clinical and diagnostic perspective from India.  
540 *Immunogenetics* 2021.
- 541 39. Ravindra K, Ahlawat A. Five probable factors responsible for COVID-  
542 associated mucormycosis outbreak in India. *Int J Infect Dis* 2021.
- 543 40. Sahu RK, Salem-Bekhit MM, Bhattacharjee B, et al. Mucormycosis in  
544 Indian COVID-19 Patients: Insight into Its Patho-Genesis, Clinical  
545 Manifestation, and Management Strategies. *Antibiotics (Basel)* 2021;  
546 10(9).
- 547 41. Segrelles-Calvo G, de SAGR, Llopis-Pastor E, et al. *Candida* spp. co-  
548 infection in COVID-19 patients with severe pneumonia: Prevalence study  
549 and associated risk factors. *Respir Med* 2021; 188: 106619.
- 550 42. Arastehfar A, Carvalho A, Nguyen MH, et al. COVID-19-Associated  
551 Candidiasis (CAC): An Underestimated Complication in the Absence of  
552 Immunological Predispositions? *J Fungi (Basel)* 2020; 6(4).



- 553 43. Roubary M, Kumar S, Kumar A, Cernakova L, Nikoomanesh F,  
554 Rodrigues CF. Overview on the Prevalence of Fungal Infections, Immune  
555 Response, and Microbiome Role in COVID-19 Patients. *J Fungi (Basel)*  
556 2021; 7(9).
- 557 44. Abdoli A, Falahi S, Kenarkoohi A. COVID-19-associated opportunistic  
558 infections: a snapshot on the current reports. *Clin Exp Med* 2021.
- 559 45. Grau S, Hernandez S, Echeverria-Esnal D, et al. Antimicrobial  
560 Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the  
561 COVID-19 Pandemic. *Antibiotics (Basel)* 2021; 10(8).
- 562 46. Ramos-Martinez A, Pintos-Pascual I, Guinea J, et al. Impact of the  
563 COVID-19 Pandemic on the Clinical Profile of Candidemia and the  
564 Incidence of Fungemia Due to Fluconazole-Resistant *Candida*  
565 *parapsilosis*. *J Fungi (Basel)* 2022; 8(5).
- 566
- 567

568 **Figure Legends**

569

570 **Figure 1. Geographical distribution of the different genotypes of FLZ-**  
571 **resistant isolates.** The pie charts denote the distribution of the different  
572 genotypes in different tertiary hospitals from different metropolitan areas in  
573 Spain.

574

575

576 **Figure 2. Minimal Spanning Tree showing the genetic proximity of**  
577 **susceptible and FLC-resistant isolates from *Candida parapsilosis*.** The  
578 numbers denote the genotype identified in each group. Straight bold lines  
579 denote groups that only differentiate in one marker. These groups are  
580 highlighted with the color shadows in the background. Orange: resistant strains;  
581 Green: susceptible strains; Blue: susceptible increased exposure (I) strains. For  
582 origin and description of the strains in each genotype, see supplemental table 1.

583

584 **Table 1.** Oligonucleotides designed to sequence the *Candida parapsilosis*  
585 *ERG11* gene (F, forward; R, reverse).

586

Oligonucleotide name	Sequence (5' - 3')
01_F_CpERG11	CGTCAAATGTCAGCATCGTC
02_R_CpERG11	TCATTTCGAGGTGAGTCAAC
03_F_CpERG11	TGGGTTGGTTCAGCCGTATC
05_F_CpERG11	ACCATCTTCACTGCATCTAG
07_F_CpERG11	GTTGCATTTGGCTGAGAAGC
09_F_CpERG11	CCAAAGGTGTTAGCTCTTCG
10_R_CpERG11	GACATAGGCAAACGTTCACC
08_R_CpERG11	CCACCTTTACCAGATAAGGC
06_R_CpERG11	GCATACAATTGAGCAAATGAAGC
04_R_CpERG11	CCAAGTACACCGTCATTACTC

587

588

589

590 **Table 2:** Distribution of the percentage of MICs to FLUCONAZOLE of *C.*  
 591 *parapsilosis* strains received at the SMRL since 2000. The table include the  
 592 number of strains analysed each year, and the % of susceptible (S), susceptible  
 593 increased exposure (I) and resistant (R) isolates.  
 594

Year	MIC (mg/L)											N	% S	% I	% R
	SUSCEPTIBLE					I	RESISTANT								
	0.125	0.25	0.5	1	2	4	8	16	32	64	>64				
2000	2	33	35	16	12	2	0	0	0	0	0	43	98	2	0
2001	1	30	53	12	1	3	0	0	0	0	0	74	97	3	0
2002	8	36	48	5	3	0	0	0	0	1	0	80	99	0	1
2003	11	40	41	5	1	0	1	1	0	0	0	115	98	0	2
2004	7	35	44	9	5	0	0	0	0	0	0	75	100	0	0
2005	18	41	32	6	1	0	0	0	1	0	0	82	99	0	1
2006	3	27	49	17	3	1	0	0	0	0	0	71	99	1	0
2007	3	24	56	8	6	0	1	0	0	0	1	71	97	0	3
2008	3	27	55	5	3	1	1	0	2	0	1	92	95	1	4
2009	0	12	78	4	0	0	4	1	0	0	0	73	95	0	5
2010	9	11	64	9	2	0	2	4	0	0	0	55	95	0	5
2011	5	14	59	14	0	0	9	0	0	0	0	22	91	0	9
2012	14	14	50	23	0	0	0	0	0	0	0	22	100	0	0
2013	0	14	57	21	0	0	7	0	0	0	0	14	93	0	7
2014	15	12	46	23	0	0	0	0	0	4	0	26	96	0	4
2015	0	2	61	37	0	0	0	0	0	0	0	46	100	0	0
2016	0	17	48	17	9	4	4	0	0	0	0	23	91	4	4
2017	9	22	39	4	4	4	4	9	4	0	0	23	78	4	17
2018	0	15	85	0	0	0	0	0	0	0	0	13	100	0	0
2019	18	9	9	18	9	9	0	0	9	0	18	11	64	9	27
2020	3	6	20	6	0	2	8	20	12	17	5	66	35	1.5	63.5
2021	3	13	12	1	4	3	10	36	11	5	1	204	33	3	64

595

596

597 Cells in orange: Mode (most frequent value)

598 In yellow: left and right values to the mode

599

600

601

602 **Table 3:** Distribution of the percentage of MIC to VORICONAZOLE of *C.*  
 603 *parapsilosis* strains received at the SMRL since 2000. The table include the  
 604 number of strains analysed each year, and the % of susceptible (S), susceptible  
 605 increased exposure (I) and resistant (R) isolates.  
 606

Year	MIC (mg/L)											N	% S	% I	% R	
	SUSCEPTIBLE				I	RESISTANT										
	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8					
2000	79	14	7	0	0	0	0	0	0	0	0	42	100	0	0	
2001	73	23	1	3	0	0	0	0	0	0	0	74	100	0	0	
2002	85	14	0	0	0	1	0	0	0	0	0	80	99	0	1	
2003	88	11	0	1	0	0	0	0	0	0	0	94	100	0	0	
2004	96	4	0	0	0	0	0	0	0	0	0	75	100	0	0	
2005	93	6	0	0	1	0	0	0	0	0	0	82	99	1	0	
2006	94	4	1	0	0	0	0	0	0	0	0	71	100	0	0	
2007	89	6	4	0	0	0	0	0	0	0	1	71	99	0	1	
2008	90	4	0	2	0	1	1	1	0	0	0	92	97	0	3	
2009	89	5	1	3	1	0	0	0	0	0	0	73	99	1	0	
2010	85	4	4	5	2	0	0	0	0	0	0	55	98	2	0	
2011	86	9	0	5	0	0	0	0	0	0	0	22	100	0	0	
2012	77	18	5	0	0	0	0	0	0	0	0	22	100	0	0	
2013	79	14	0	7	0	0	0	0	0	0	0	14	100	0	0	
2014	69	23	4	0	0	0	4	0	0	0	0	26	96	0	4	
2015	89	9	0	2	0	0	0	0	0	0	0	46	100	0	0	
2016	70	13	13	4	0	0	0	0	0	0	0	23	100	0	0	
2017	57	26	0	9	0	4	4	0	0	0	0	23	91	0	9	
2018	87	0	0	0	0	13	0	0	0	0	0	15	87	0	13	
2019	36	36	0	0	0	9	0	18	0	0	0	11	73	0	27	
2020	27	8	0	2	2	24	36	2	0	0	0	66	36	2	62	
2021	28	2	3	5	25	27	7	1	1	0	0	204	38	25	37	

607

608

609 Cells in orange: Mode (most frequent value)

610 In yellow: left and right values to the mode

611

612

613 **Table 4:** Distribution of the percentage of MIC to ITRACONAZOLE of *C.*  
 614 *parapsilosis* strains received at the SMRL since 2000.

615

616

YEAR	MIC (mg/L)											N	% S	% R
	SUSCEPTIBLE				RESISTANT									
	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8			
2000	58	30	9	2	0	0	0	0	0	0	0	43	100	0
2001	30	55	11	4	0	0	0	0	0	0	0	74	100	0
2002	25	56	18	0	1	0	0	0	0	0	0	80	99	1
2003	50	36	12	1	0	1	0	0	0	0	0	115	99	1
2004	61	31	7	1	0	0	0	0	0	0	0	75	100	0
2005	52	41	6	0	0	0	0	0	0	0	0	82	100	0
2006	73	20	6	1	0	0	0	0	0	0	0	71	100	0
2007	63	25	8	1	0	0	0	0	0	0	1	71	99	1
2008	52	40	4	0	2	1	0	0	0	0	0	92	97	3
2009	78	21	0	1	0	0	0	0	0	0	0	73	100	0
2010	95	0	2	2	2	0	0	0	0	0	0	55	98	2
2011	86	9	5	0	0	0	0	0	0	0	0	22	100	0
2012	95	5	0	0	0	0	0	0	0	0	0	22	100	0
2013	71	29	0	0	0	0	0	0	0	0	0	14	100	0
2014	65	23	4	0	4	4	0	0	0	0	0	26	92	8
2015	72	28	0	0	0	0	0	0	0	0	0	46	100	0
2016	35	22	30	13	0	0	0	0	0	0	0	23	100	0
2017	26	35	22	9	9	0	0	0	0	0	0	23	91	9
2018	7	20	67	7	0	0	0	0	0	0	0	15	100	0
2019	9	18	36	27	9	0	0	0	0	0	0	11	91	9
2020	15	20	41	23	2	0	0	0	0	0	0	66	98	2
2021	23	28	22	20	6	1	1	0	0	0	0	204	89	11

617

618 Cells in orange: Mode (most frequent value)

619 In yellow: left and right values to the mode

620

621 **Table 5:** Distribution of the percentage of MIC to POSACONAZOLE of *C.*  
 622 *parapsilosis* strains received at the SMRL since 2000

623  
 624  
 625

YEAR	MIC (mg/L)											N	% S	% R
	SUSCEPTIBLE			RESISTANT										
	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8			
2001	55	45	0	0	0	0	0	0	0	0	0	11	100	0
2002	65	31	4	0	0	0	0	0	0	0	0	80	100	0
2003	80	19	1	0	0	0	0	0	0	0	0	94	100	0
2004	83	17	0	0	0	0	0	0	0	0	0	75	100	0
2005	65	33	2	0	0	0	0	0	0	0	0	82	100	0
2006	87	13	0	0	0	0	0	0	0	0	0	70	100	0
2007	87	11	0	0	0	0	0	0	1	0	0	71	99	1
2008	70	26	1	1	1	1	0	0	0	0	0	92	97	3
2009	81	19	0	0	0	0	0	0	0	0	0	73	100	0
2010	74	20	2	2	2	0	0	0	0	0	0	54	96	4
2011	95	5	0	0	0	0	0	0	0	0	0	22	100	0
2012	91	9	0	0	0	0	0	0	0	0	0	22	100	0
2013	93	7	0	0	0	0	0	0	0	0	0	14	100	0
2014	92	4	4	0	0	0	0	0	0	0	0	26	100	0
2015	78	20	2	0	0	0	0	0	0	0	0	46	100	0
2016	22	52	22	4	0	0	0	0	0	0	0	23	96	4
2017	26	57	13	4	0	0	0	0	0	0	0	23	96	4
2018	13	47	33	7	0	0	0	0	0	0	0	15	93	7
2019	18	36	36	9	0	0	0	0	0	0	0	11	91	9
2020	35	39	23	3	0	0	0	0	0	0	0	66	97	3
2021	23	38	20	12	4	2	1	0	0	0	0	204	81	19

626  
 627  
 628  
 629  
 630  
 631

Cells in orange: Mode (most frequent value)

In yellow: left and right values to the mode

632 **Table 6:** Distribution of the percentage of MIC to ISAVUCONAZOLE of *C.*  
633 *parapsilosis* strains received at the SMRL since 2016

634

635

YEAR	MIC (mg/L)											N
	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8	
2016	86	14	0	0	0	0	0	0	0	0	0	7
2017	75	15	5	0	5	0	0	0	0	0	0	20
2018	87	7	7	0	0	0	0	0	0	0	0	15
2019	64	18	9	0	0	9	0	0	0	0	0	11
2020	30	14	41	9	0	0	0	0	0	0	0	62
2021	38	23	29	7	2	1	1	0	0	0	0	196

636

637 Cells in orange: Mode (most frequent value)

638 In yellow: left and right values to the mode

639

640

641

642

643

644



645 **Table 7. Mutations in the *ERG11* gene found in susceptible, susceptible**  
646 **increased exposure (I) and resistant strains to fluconazole.** For each  
647 category, we also include the susceptibility profile (S/I/R) for voriconazole. HET:  
648 heterozygous; HOMO: homozygous.

649  
650  
651

<i>ERG11</i> Mutation	FLC Susceptible	FLC Susceptible increased exposure			FLC Resistant		
		VOR_S	VOR_S	VOR_I	VOR_R	VOR_S	VOR_I
WT	34	1	1	0	5	1	6
Y132F_HET	0	3	1	0	1	17	38
Y132F_HOMO	0	0	0	1	5	29	87

652  
653  
654

655 **Table 8. Susceptibility profile of WT or mutant strains harboring the Y132F**  
 656 **in homozygosity (HOMO) or heterozygosity (HET).**



657

Antifungal	<i>ERG11</i> mutation	N	Antifungal susceptibility (mg/L)			
			Median	Geometric Mean	Minimal	Maximal
Fluconazole	WT	43	0.5	0.78	0.125	>64
	Y132F_HET	57	16	12.5	4	32
	Y132F_HOM	108	16	26.1	16	>64
Voriconazole	WT	43	0.031	0.032	0.016	4
	Y132F_HET	57	0.5	0.39	0.125	1
	Y132F_HOM	108	0.5	0.5	0.06	2
Itraconazole	WT	43	0.03	0.033	0.016	1
	Y132F_HET	57	0.125	0.10	0.031	0.25
	Y132F_HOM	108	0.06	0.05	0.016	0.25
Posaconazole	WT	43	0.03	0.029	0.016	0.25
	Y132F_HET	57	0.06	0.065	0.016	0.5
	Y132F_HOM	108	0.031	0.035	0.016	0.125
Isavuconazole	WT	43	0.016	0.021	0.016	1
	Y132F_HET	57	0.06	0.067	0.031	0.125
	Y132F_HOM	108	0.031	0.039	0.016	0.5


658

659


660





**Burgos**



**Santander**



**Madrid**



**Barcelona**

